Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hepatitis B Vaccine in Patients With Inflammatory Bowel Disease (HBV VIP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01531075
Recruitment Status : Completed
First Posted : February 10, 2012
Last Update Posted : April 21, 2020
Sponsor:
Information provided by (Responsible Party):
Ohad Etzion, Soroka University Medical Center

Brief Summary:
The objective is to assess the efficacy of Hepatitis B Virus vaccination in a population of IBD patients treated with immunosuppressive medications.

Condition or disease Intervention/treatment Phase
Inflammatory Bowel Disease Biological: ENGERIX-B (HBV Vaccine) Biological: Sci-B-Vac Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 91 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Assessment of Hepatitis B Vaccination Efficacy in Patients With Inflammatory Bowel Diseases
Actual Study Start Date : April 2012
Actual Primary Completion Date : August 2015
Actual Study Completion Date : August 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ENGERIX-B Biological: ENGERIX-B (HBV Vaccine)
ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
Other Name: ENGERIX-B

Experimental: Sci-B-Vac Biological: Sci-B-Vac
Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.




Primary Outcome Measures :
  1. protective level of anti HBs antibodies [ Time Frame: 1 month after the last does of vaccine ]

    Antibody titer >10 IU/ml 30 days following last vaccine dose will be considered protective.

    In the work done by Altunoz et al., titer rate below 10 IU was observed in 40% of the patients, while 40% of the patients achieved a rate of above 100 IU. Therefore, we can estimate that the geometric mean of distribution is approx. 50 IU. A sample size of 37 patients in each group achieves a power of 80% to detect a ratio above 1.37 between the two vaccinated groups.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male/female ≥ 18 years of age
  • Evidence of IBD as diagnosed by clinical, laboratory imaging and endoscopic criteria.
  • Treated with at least one immunosuppressive medication at the time of study initiation
  • Provided written informed consent.

Exclusion Criteria:

  • Pregnant women
  • Diagnosis of chronic viral hepatitis B
  • Any major acute medical event in the 30 days prior to recruitment that necessitated hospitalization ( acute myocardial infarction, CVA, pulmonary emboli, sepsis, major trauma)
  • Any other chronic inflammatory condition not related to IBD ( connective tissue disease, Chronic liver disease, COPD, poorly controlled diabetes mellitus)
  • Active hematologic or oncologic diseases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01531075


Locations
Layout table for location information
Israel
Soroka UMC
Beer- Sheva, Israel, 84101
Sponsors and Collaborators
Soroka University Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Ohad Etzion, MD Soroka UMC
Layout table for additonal information
Responsible Party: Ohad Etzion, Senior physician, Department of Gastroenterology and Liver Disease, Soroka University Medical Center
ClinicalTrials.gov Identifier: NCT01531075    
Other Study ID Numbers: sor026511ctil
First Posted: February 10, 2012    Key Record Dates
Last Update Posted: April 21, 2020
Last Verified: April 2020
Keywords provided by Ohad Etzion, Soroka University Medical Center:
HBV, Inflammatory bowel disease, immunosuppressor
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis B
Intestinal Diseases
Inflammatory Bowel Diseases
Hepatitis
Liver Diseases
Digestive System Diseases
Hepadnaviridae Infections
DNA Virus Infections
Virus Diseases
Hepatitis, Viral, Human
Gastrointestinal Diseases
Gastroenteritis